These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 34071787)

  • 1. Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan.
    Chang C; Huang CH; Tseng HJ; Yang FC; Chien RN
    J Pers Med; 2021 May; 11(6):. PubMed ID: 34071787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
    Jesudian AB; Ahmad M; Bozkaya D; Migliaccio-Walle K
    J Manag Care Spec Pharm; 2020 Jun; 26(6):750-757. PubMed ID: 32463782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence.
    Flamm SL
    Therap Adv Gastroenterol; 2011 May; 4(3):199-206. PubMed ID: 21694804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of rifaximin in combination with lactulose in end-stage liver disease patients with MELD greater than 20: a single center experience.
    Mantry PS; Mehta A; Graydon R
    Transplant Proc; 2014 Dec; 46(10):3481-6. PubMed ID: 25498076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
    Volk ML; Burne R; Guérin A; Shi S; Joseph GJ; Heimanson Z; Ahmad M
    J Med Econ; 2021; 24(1):202-211. PubMed ID: 33464935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
    Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
    Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons from "real life experience" of rifaximin use in the management of recurrent hepatic encephalopathy.
    Chautant F; Guillaume M; Robic MA; Cadranel JF; Peron JM; Lison H; Cool C; Bureau C; Duhalde V
    World J Hepatol; 2020 Jan; 12(1):10-20. PubMed ID: 31984117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
    Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
    Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 13.  Minimal hepatic encephalopathy in cirrhosis- how long to treat?
    Goyal O; Sidhu SS; Kishore H
    Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy for the treatment and prevention of hepatic encephalopathy.
    Mohammad RA; Regal RE; Alaniz C
    Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of rifaximin response in hepatic encephalopathy.
    Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
    J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
    Hudson M; Schuchmann M
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
    Fritz MK; Mangino AA; Hunt TV; Pitcock CT; Dugan AJ; Karri K; Yarra P
    Ann Pharmacother; 2023 Aug; 57(8):899-906. PubMed ID: 36367093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
    Sanyal AJ; Kowdley KV; Reau NS; Pyrsopoulos NT; Allen C; Heimanson Z; Bajaj JS
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.